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SIGNIFICANCE OF IMMUNOHISTOCHEMISTRY IN ACCURATE
CHARACTERIZATION OF MALIGNANT TUMORS
Zubair Ahmed, Najamul Sahar Azad, Yasmeen Bhurgari, Rashida Ahmed, Naila Kayani,
Shahid Pervez, Sheema Hasan
Department of Pathology & Microbiology, The Aga Khan University Hospital, Stadium Road, Karachi, Pakistan

Background: To determine in a large series of surgical biopsies the role and significance of
immunohistochemistry in the adequate and accurate characterization of malignant tumors.
Methods: A retrospective study of 20,000 consecutive surgical biopsies reported in the Section of
Histopathology, AKU in 2003. Data was obtained by retrieving the filed surgical biopsy reports in
the section. Results and Conclusions: Out of the 20,000 biopsies, 6534 (32.67%) were
neoplastic. 4726 neoplasms (72.33%) were malignant, and 1808 (27.67%) were benign.
Immunohistochemistry was performed on 29.49% of malignant tumors, and 4.97% of benign
tumors. Immunos were performed on only 2.82% of routine squamous cell carcinomas and
adenocarcinomas of various organs, and in only 1.9% of infiltrating breast carcinomas, the
commonest malignant tumors in females. In contrast, immunos were performed on 97.12% of
non-Hodgkin’s lymphomas, 97.94% of Hodgkin’s lymphomas, 98.09% of malignant spindle cell
neoplasms, 87.96% of small round blue cell tumors of childhood, 87.30% of neuroendocrine
neoplasms, and 84.37% cases of malignant melanomas. In addition, immunos were performed on
all cases of malignant undifferentiated neoplasms and were able to resolve the issue in over 89%
of such cases. Immunos were also performed on 54.74% of metastatic tumors. Lymph nodes were
the commonest organs on which immunos were performed i.e. 96.50% of lymph node tumors,
followed by CNS and renal neoplasms with 33.01% and 25.92% respectively.
Key Words: Malignant tumours, Karachi, Immunochemistry
Histopathology at the Aga Khan University Hospital
(AKUH) has state of the art immunohistochemistry
facilities and a large, diverse and ever-expanding
panel of antibodies is available. This has proved
invaluable in the development of our section as the
major referral center especially for tumor pathology
in Pakistan.
The aim of our study was to determine in a
large series of surgical biopsies, the role and
significance of immunohistochemistry in the
adequate and accurate characterization of malignant
tumors.

INTRODUCTION
The histologic diagnosis of cancer and the
categorization of the proper tumor type is essential
for the adequate treatment of malignant tumors.
Histologic
subtyping
with
the
help
of
immunohistochemical characterization of tumors has
resulted in a level of distinction between diagnoses
which was not previously possible. In addition to
substantiating the diagnosis of malignancy, this
subtyping provides information which is essential in
guiding
therapy.
The
distinction
between
histologically similar tumors is often critical as
therapeutic options often differ.1
Immunohistochemistry has emerged as the
most valuable adjunct to Hematoxylin and Eosin
(H&E) staining in diagnostic histopathology.2 No
other method during the past fifty years has had such
a major impact on histopathology.3 This technique
has equipped the histopathologist with the tools
needed to tackle the most common diagnostic
problems in tumor pathology especially the
characterization of the undifferentiated or poorly
differentiated malignant tumors, whether primary or
metastatic.4-6 The impact of immunohistochemistry
has been enhanced by the large number of good
quality antibodies that are available commercially
and improvements in antigen retrieval techniques.7
No modern histopathology laboratory can
hope
to
function
without
adequate
immunohistochemistry facilities. The section of

MATERIAL AND METHODS
A retrospective study of 20,000 consecutive surgical
biopsies reported in the section of Histopathology,
AKUH in 2003. Data was obtained by retrieving the
filed surgical biopsy reports in the section.
The immunohistochemistry technique used
is a combination of immunocytochemistry, which
attaches the tracer to the specific antigen within the
tissue sections, and standard enzyme histochemistry
which visualizes the tracer for bright field or electron
microscopy.
Several procedures are available. The two
most commonly used are the peroxidase
antiperoxidase immune complex method and the
biotin avidin immunoenzymatic technique. In the
latter, the high affinity of avidin for biotin is used to
couple the peroxidase label to the primary antibody.
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We use the envision system. This is a two
step immunohistochemistry staining technique. This
is based on an HRP labeled polymer against which
primary antibodies produced in mice react well.
These primary mouse antibodies are supplied by the
user. The combination then reacts with the antigens
in paraffin embedded tissues cryostat tissues etc.
Tissues processed in a variety of fixatives may be
used. The procedure used is described in table 1.
It is of utmost importance to use fresh
solutions; make sure antibody is not expired, run
appropriate controls for every batch of each antibody.
It is recommended that immunos are done on all
cases of Non-Hodgkin’s and Hodgkin’s lymphoma,
all cases of undifferentiated malignant neoplasms, all
sarcomas for further characterization, in metastatic
tumors, sometimes even in benign lesions for
adequate characterization and on cytology cell
blocks.

Table-1: Distribution of cases on the basis of
biological behavior and morphology

Category of
Lesion

Total
Number

Malignant
Benign
All Tumors
Non-neoplastic
All Lesions

4726
1808
6534
13,466
20,000

Number of
cases on
which
immunos
were
performed
1394
73
1467
59
1526

Percentage
of cases on
which
immunos
were
performed
29.49%
4.97%
22.45%
0.44%
7.63%

Table 2: Distribution of cases on the basis of
morphology
Morphology
Non-Hodgkin’s lymphoma
382
Hodgkin’s lymphoma
97
Malignant Spindle cell
157
neoplasms
Small round blue cell tumors
108
Neuroendocrine tumors.
63
Malignant melanomas
32

RESULTS
Out of the 20,000 consecutive biopsies, 6534
(32.67%) were neoplastic and 13,466 (67.33%) were
non-neoplastic. Of the neoplastic lesions 4726
(72.33%) were malignant, while 1808 (27.67%) were
benign. Immunohistochemistry was performed on
29.49% of malignant tumors.(Table-1)
Very few (2.82%) of the routine squamous
cell carcinomas, adenocarcinomas of various organs
required immunohistochemistry. These carcinomas
comprised a large chunk of malignant tumors. There
were 1665 cases of such ordinary types of carcinoma
and another 736 infiltrating carcinomas of the breast.
Together, these 2401 tumors comprised 50.80% of all
malignant tumors. But immunohistochemistry was
required in only a tiny percentage of these cases.
Infiltrating carcinomas of the breast, which comprise
the commonest malignant tumors in females required
immunohistochemistry in only 1.9% cases. On the
other hand, immunohistochemistry was performed on
97.12% of Non Hodgkin’s lymphomas, 97.94% of
Hodgkin’s lymphomas, 98.09% of malignant spindle
cell neoplasms, 87.96% of small round blue cell
tumors of childhood, 87.30% of neuroendocrine
neoplasms, and 84.37% cases of malignant
melanomas. (Table-2)
Malignant
undifferentiated
neoplasms
required immunohistochemistry in all cases (n=213).
Immunohistochemistry allowed accurate diagnosis in
190 of these cases (89.20%). In less than 11% such
cases, immunohistochemistry was unhelpful.
Metastatic tumors (n=316) comprised 6.69% of all
malignant tumor. Immunohistochemistry was
performed in 173 out of 316 metastatic tumors or
54.74%.

371
95

97.12%
97.94%

154

98.09%

95
55
27

87.96%
87.30%
84.37%

Table 3: Distribution of cases on the basis of site
of origin

Organ / Tissue

Lymph nodes
CNS
Kidney
Testis
Bone
Liver
Ovary
Thyroid
Salivary Gland
Skin *
U. Bladder
Vascular
Prostate

Total
Number

372
212
54
44
137
60
242
69
71
143
129
142
126

Number
of cases on
which
immunos
were
performed
359
70
14
11
27
7
26
6
6
11
8
8
5

Percentage
of cases on
which
immunos
were
performed
(96.50 %)
(33.01 %)
(25.92 %)
(25 %)
(19.71 %)
(11.66 %)
(10.74 %)
(8.69 %)
(8.45 %)
(7.69 %)
(6.20 %)
(5.63 %)
(3.97 %)

*squamous cell carcinomas not included
In 73 of these 173 cases (23.74%), CK 7 and
CK 20 antibodies were utilized to give accurate
information about the site of the primary tumor.
Certain neoplasms like gastrointestinal stromal tumor
(GIST), anaplastic large cell (Ki 1) lymphoma
(ALCL),
mesothelioma
etc.
required
immunohistochemistry in all cases. Among specific
organs, immunohistochemistry was performed on
96.50% of lymph node neoplasms, followed by CNS
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neoplasms (33.01%) and renal neoplasms (25.92%).
(Table-3).

Hodgkin’s
lymphomas
are
confirmed
by
immunohistochemistry.
In some cases it may be difficult to
differentiate Hodgkin’s lymphomas from anaplastic
large cell (ki 1) lymphoma (ALCL) or diffuse large B
cell lymphoma. ALCL can only be diagnosed by
immunohistochemistry. In all suspected cases of
Non-Hodgkin’s and Hodgkin’s lymphomas, a panel
of antibodies including LCA (CD45), CD 20 and CD
79 (Pan B markers), CD 3 and UCHL 1 (Pan T
markers), CD15 (GAA) and CD 30 (ki 1) are used. In
suspected cases of ALCL, Epithelial membrane
antigen (EMA) and ALK protein an also used.12,13
We are now diagnosing a large number of cases of
ALCL which in the past may have been
misdiagnosed as Hodgkin’s lymphoma or Diffuse
Large B cell lymphoma.
Antibodies such as bel-2 and CD 10 can
distinguish between reactive follicular hyperplasia
and follicular lymphoma in difficult cases.14,15 There
are prognostic and therapeutic differences between B
and T Non-Hodgkin’s Lymphomas as well as
Hodgkin’s
lymphoma
which
make
immunohistological characterization very important.
Immunohistochemistry is also performed on most
cases of malignant spindle cell neoplasms (soft tissue
sarcomas) for their accurate characterization (Table
2). The few cases in which immunos were not
performed were those in which only slides were
received or external blocks which showed marked
processing
artifact.
On
the
basis
of
immunohistochemistry, soft tissue sarcomas can be
accurately
classified
as
fibrosarcomas,
leiomyosarcomas, malignant peripheral nerve sheath
tumors etc. The specific types of soft tissue sarcomas
have prognostic and therapeutic difference which
makes their accurate characterization very important.
Also, the diversity of these tumors, their
differentiation along several lines, and the difficulties
often faced in their differential diagnosis with benign
pseudosarcomatous lesions and non-mesenchymal
malignant tumors makes their accurate typing with
immunohistochemistry very important.2
Gastrointestinal stromal tumors (GISTs),
distinctive type of stromal tumors occurring in the
GIT, must be distinguished from other mescenchymal
tumors arising in the GIT. Immunohistochemistry is
essential in the diagnosis of these neoplasms.
The CD117 (c-kit) is a proto-oncogene
which encodes a transmembrane tyrosine kinase
receptor is normally expressed by the interstitial cells
of Cajal in GIT. In GISTs, a c-kit mutation occurs
and is thought to be the direct cause of the tumor.16
CD 117 is positive in 85-100% cases of GISTs17 and
this positivity requires to be demonstrated for the
patient to receive the new effective treatment i.e. STI

DISCUSSION
The optimal treatment of patients with cancer
depends on establishing accurate diagnoses by using
a complex combination of clinical and
histopathological data. In some instances, this task is
difficult or impossible because of atypical clinical
presentation or histopathology.
With advances in the treatment of cancers,
surgeons and oncologists now demand accurate
characterization of malignant tumors. And with
histopathology also developing spectacularly as a
science, it has now become possible in the large
majority of cases to accurately subtype malignant
tumors histologically. Immunohistochemistry is the
most important tool that has made this possible. Its
advantages include its remarkable sensitivity and
specificity, its applicability to routinely processed,
formalin fixed material, and compatibility to most
common fixatives.8
Recognizing
the
importance
of
immunohistochemistry in tumor pathology, the
section of Histopathology, AKU has developed
excellent immunohistochemistry facilities, which are
provided
in
cases
which
require
immunohistochemistry, without any additional
charge from the patient, despite the use of one to
more than ten antibodies used per case, with an
average of four to five.
However, there is no over-dependence on
immunohistochemistry. Immunos were performed on
only 29.49% of all malignant tumors where accurate
diagnosis and characterization of tumors was not
possible. In Pakistan, where histopathology is still
evolving as a science and most centers lack
immunohistochemistry facilities, it is imperative that
a major referral center like AKU should utilize this
technique in order to provide accurate diagnosis. A
study conducted by Ahmed et al9 showed that lack of
immunohistochemistry facilities can result in
significant differences in diagnosis in difficult cases.
As
shown
in
our
results,
immunohistochemistry is performed in all malignant
undifferentiated neoplasms and the use of extensive
panels of antibodies in such cases allows accurate
histologic diagnosis in more than 89% cases.
Immunohistochemistry is performed in all cases of
suspected Non-Hodgkin’s and Hodgkin’s lymphoma.
The few cases (Table 2) in which it was not
performed were those cases in which only slides were
sent for second opinion and no blocks were available.
All Non-Hodgkin’s lymphomas are phenotyped into
B or T cell types according to the WHO / REAL
classification of lymphoid neoplasms.10,11 Similarly
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571.18 With the use of this antibody in all suspected
cases of GIST, we are now diagnosing these tumors
with increasing frequency. These tumors in the past
would have been characterized as smooth muscle or
nerve sheath tumors.
Similarly
immunohistochemistry
is
performed in the overwhelming majority of small
round blue cell tumors of childhood (Table 2). The
few cases in which immunos were not performed
included
lesions
such
as
retinoblastoma,
nephroblastoma (Wilm’s tumor) etc. However,
immunos are essential in differentiating between
rhabdomyosarcoma,
ewing’s sarcoma/primitive
neuroectodermal tumor (PNET), lymphoma etc. In
few other cases, immunos were not performed for the
same reasons outlined above for other tumors.
Neuroendocrine
neoplasms
comprise
another diverse category which often present
difficulties in diagnosis and also need to be
accurately classified for prognostic and therapeutic
reasons. Again, immunos were performed in a large
majority of these cases in the form of a panel of
antibodies including S-100 protein, Neuron specific
enolase (NSE), chromogranin, synaptophysin and
Neurofilament resulting in their accurate diagnosis
(Table 2).
Malignant melanomas, in most cases, are
also confirmed by immunohistochemistry by using a
panel of antibodies i.e. cytokeratins (negative in
melanoma), S100 profein, vimentin and HMB 45
(positive in melanoma). HMB 45 is a highly specific
marker for melanoma.19
Immunohistochemistry is essential for the
diagnosis of malignant mesothelioma of the pleura
and to differentiate if from metastatic lung
adenocarcinoma. We perform immunos on all pleural
biopsies with malignant neoplasms using a panel of
antibodies, Calretinin-Thrombomodulin-Cytokeratin
5/6 (positive in mesothelioma, negative in
adenocarcinoma) and Ber EP4 (negative in
mesothelioma, positive in adenocarcinoma).20-22
Similarly, immunohistochemistry is almost always
performed in other biphasic neoplasms such as
synovial sarcoma for confirmation by employing
antibodies such as EMA, cytokeratins, bcl-2 and
CD99 (MIC2).2, 23, 24
As shown in the results, very tiny
percentages of ordinary carcinomas of various organs
(e.g. Skin, esophagus, lungs, stomach, colorectum,
endometrium etc) needed immunohistochemistry for
confirmation (only less well differentiated cases) and
similar was the case with infiltrating ductal
carcinomas of breast which required immunos only
when there was very little material or crushed
material in trucut biopsy specimens and when there
was need to exclude malignant lymphoma in such

small specimens. So although these non-specific
carcinomas of various organs (including breast)
comprised a large chunk of malignant tumors,
immunos were required in very few cases.
According
to
the
results,
immunohistochemistry was performed on 54.74% of
metastatic tumors. esp. tumors in lymph nodes, brain,
liver etc to rule out primary neoplasms of these
organs. In lymph nodes, cytokeratins together with
lymphoid markers were used. In the brain,
cytokeratins were used together with glial fibrillary
acidic protein (GFAP) to rule out a high grade
astrocytoma.25 In the liver, cytokeratins CAM 5.2 and
AE1/AE3 were used in poorly differentiated cases.
These two antibodies are of great value in
distinguishing between a primary hepatocellular
carcinoma and metastatic carcinoma in difficult cases
as hepatocellular carcinoma is positive for CAM 5.2
and negative for AE1/AE3, while metastatic
carcinomas to liver are positive to both markers.26 In
23.74% of metastatic tumors, CK7 and CK20 were
used especially in cases of metastases occurring in
omentum, mesentery etc. These antibodies often
allowed us to predict the site of origin of the primary
tumor since specific tumors are either positive or
negative to one or both these markers.4 CK7 and CK
20, together with Prostate Specific Antigen (PSA) are
also very useful in cases of poorly differentiated
carcinoma of bladder and prostate where it cannot be
determined histologically whether the tumor is of
bladder or prostatic origin. Urothelial carcinomas of
bladder are CK7 and CK20 positive, and PSA
negative, while the opposite is true for prostatic
adenocarcinoma. In spinal metastases, we use PSA to
conform that a metastatic adenocarcinoma represents
a primary from the prostates.27
Table 3 shows the numbers and percentages
of malignant tumors in specific organs on which
immunohistochemistry
is
performed.
Not
surprisingly, lymph nodes are at the top of the list
owing to the fact that immunos are performed in
almost all cases of Non-Hodgkin’s and Hodgkin’s
lymphomas. Tumors of the CNS are next due to the
diversity of CNS neoplasms and the common
occurrence of metastases in the CNS. More
surprising is the fact that renal neoplasms are number
three on the list, but it must be kept in mind that these
include not only renal cell carcinomas, but other
tumors as well. Other organs on which immunos are
commonly performed include testis, bone, liver etc.
As
shown
in
the
results,
immunohistochemistry was also performed on 4.97%
of benign tumors. These were those tumors which
proved difficult to characterize accurately by H&E
alone. Immunohistochemistry was also performed on
0.44% of non-neoplastic cases. These were those
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cases on which H&E could not prove conclusively
whether they were neoplastic or not.
The accurate characterization of neoplastic
lesions, both malignant and benign, is also important
from an academic view point. Being a major referral
and research center for Histopathology in Pakistan,
we need to have a complete and accurate data base of
all neoplasms for research and academic purposes,
and for our data to be acceptable internationally.
Histopathology has now advanced to a stage where
accurate characterization of most neoplasms is
possible
and
should
be
attempted.
Immunohistochemistry is the most valuable tool
available to us for this purpose. If we do not update
ourselves according to new techniques, we will be
left far behind. Yet another transformation in
histopathology is now occurring which is the
application of molecular techniques to histopathology
specimens. We must welcome these and adopt them
but with a firm realization that all these are
invaluable adjuncts to meticulous gross and
microscopic examination, but cannot replace them.
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CONCLUSION
Immunohistochemistry has emerged as the most
valuable adjunct to routine H&E staining for accurate
characterization of malignant neoplasms, esp in
difficult and challenging cases. The accurate typing
of malignant as well as benign tumors is important
from diagnostic, prognostic, therapeutic, academic
and research viewpoints, and immunohistochemistry
is the main tool which has enabled the
histopathologist to achieve this goal. The process is
not cost-effective for all laboratories especially those
in smaller cities, therefore it is suggested that better
referral laboratory services should be available to
give population coverage.
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